References

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006;56:106-130.

2. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150:179-185.

3. Armstrong B, Kricker A. The epidemiology of UV induced skin cancer. J Photo-chem Photobiol B 2001;63:8-18.

4. Beddingfield III FC. The melanoma epidemic: Res Ipsa Loquitur. Oncologist 2003;8:459-465.

5. Desmond RA, Soon S. Epidemiology of malignant melanoma. Surg Clin N Am 2003;83:1-29.

6. Rager EL, Bridgeford EP, Ollila DW. Cutaneous Melanoma: Update on prevention, screening, diagnosis, and treatment. Am Fam Physician 2005;72:269-276.

7. Kuijpers DI, Thissen MR, Neumann MH. Basal cell carcinoma. Treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol 2002;3:247-259.

8. Thompson JF, Scolyer RA, Kefford RF. Cutaneous Melanoma. Lancet 2005;365:687-701.

9. Ting W, Schultz K, Cac N, et al. Tanning bed exposure increases the risk of malignant melanoma. Int J Dermatol 2007;46:1253-1257.

10. American Cancer Society, National Comprehensive Cancer Network. Melanoma: Treatment guidelines for patients. Dermatol Nursing 2005;17:119-131.

11. MacKie RM. Risk factors for development of primary cutaneous malignant melanoma. Dermatol Clinic 2002;20:597-600.

12. Poochareon RS, Federman DG, Kirsner RS. Primary prevention efforts for melanoma. J Drugs Dermatol 2004;3:506-519.

13. Gallagher RP. Sunscreens in melanoma and skin cancer prevention. CMAJ 2005;173:244-245.

14. Helfand M, Mahon SM, Eden KB, et al. Screening for Skin Cancer. Am J Prev Med 2001;20:44-58.

15. Friedman R, Heilman ER. The pathology of malignant melanoma. Dermatol Clin 2002;20:659-676.

16. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25:1129-1134.

17. Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous melanoma: Prognostic factors. Cancer Control 2005;12:223-239.

18. Garner KL, Rodney WM. Basal and squamous cell carcinoma. Dermatology 2000;27:447-457.

19. Martinez JC, Otley CC. The management of melanoma and non-melanoma Skin cancer: A review for the primary care physician. Mayo Clinic Proceedings 2001;76:1253-1265.

20. Balch CM, Buzaid AC, Soon SJ, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001;19:3635-3648.

21. Nahabedian MY. Melanoma. Clin Plast Surg 2005;32:249-259.

22. Jonasch E, Haluska FG. Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. Oncologist 2002;6:34-55.

23. Lawson DH. Choices of adjuvant therapy of melanoma. Cancer Control 2005;12:236-241.

24. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high risk melanoma: The AIM HIGH study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-duration interferon alpha 2b in high risk resected malignant melanoma. J Clin Oncol 2004;22:53-61.

25. Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/ DKG 80-1 randomized phase III trial: rIFN-alpha 2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. European J of Cancer 2004;40:390-402.

26. Kirkwood JM, Ibrahim GJ, Sondak VK, et al. High and low dose interferon alpha 2b in high risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458.

27. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-1677.

28. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alpha 2b significantly prolongs relapse free and overall survival compared with the GM2-KLH/ QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.

29. Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon alpha for high risk melanoma provide a worthwhile benefit? A meta-analysis of the randomized trials. Cancer Treat Rev 2003;29:241-252.

30. Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma. Cancer 2008;112:982-994.

31. Kefford RF. Adjuvant therapy of cutaneous melanoma: The interferon debate. Annals of Oncology 2003;14:358-365.

32. Spanknebel K, Kaufman HL. Surgical treatment of stage IV melanoma. Clinics in Dermatol 2004;22:240-250.

33. O'Day SJ, Kim CJ, Reintgen DS. Cancer Control. Metastatic Melanoma: Chemotherapy to Biochemotherapy 2002;9:31-38.

34. Atkins MB, Lotze MT, Dutcher JP, et al. High dose recombinant Interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.

35. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. Cancer J Sci Am. High dose recombinant interleukin 2 therapy in patients with metastatic melanoma: Long-term survival update 2000;6:S11-S14.

36. Buzaid AC, Atkins M. Practical guidelines for the management of biochemotherapy related toxicity in melanoma. Clin Can Res 2001;7:2611-2619.

37. Acquavella N, Kluger H, Rhee J, et al. Toxicity and activity of a twice daily high dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother 2008;31:569-576.

38. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temo-zolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 2000;18:158-166.

39. Tsao H, Atkins MB, Sober A. Management of cutaneous melanoma. NEJM 2002;351:998-1012.

40. Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high dose interferon alpha 2b therapy. J Clin Oncol 2002;20:3703-3718.

41. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a Phase III randomized trial. J Clin Oncol 2002;20:2045-2052.

42. Hamm C, Verma S, Petrella T, et al. Biochemotherapy for the treatment of metastatic malignant melanoma: A systematic review. Cancer Treat Rev 2008;34:145-156.

43. Keilholz U, Punt CJA, Gore M, et al. Dacarbazine, cisplatin, and interferon alpha 2b with or without interleukin 2 in metastatic melanoma: A randomized phase III trial (18951) of the European organization for research and treatment of cancer melanoma group. J Clin Oncol 2005;23:6747-6755.

44. NCCN Melanoma clinical practice guidelines v.1.2006, www.NCCN.org..

45. Douglas JG, Margolin K. The treatment of brain metastases from malignant melanoma. Seminars in Oncology 2002;29:518-524.

46. Tarhini AA, Agarwala SS. Management of brain metastasis in patients with melanoma. Curr Opin Oncol 2004;16:161-166.

47. Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treatment Rev 2004;30:515-520.

48. Tsao H, Sober AJ. Melanoma treatment update. Dermatol Clin 2005;23:323-333.

49. Margolin K, Atkins MB, Thompson JA, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the cytokine working group. J Cancer Res Clin Oncol 2002;128:214-218.

50. Ready N, Aronson F, Wanebo H, Kennedy T. A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alpha 2-B for metastatic malignant melanoma. Am J Clin Oncol 2005;28:479-483.

51. Hwu W, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastasis from melanoma. Cancer Control 2005;103:2590-2597.

52. Agarwala SS. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 2004;22:2101-2107.

53. Lang PG. Current concepts in the management of patients with melanoma. Am J Clin Dermatol 2002;3:401-426.

54. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002;146:1-6.

55. Chen JG, Fleischer AB, Smith ED, et al. Cost of non-melanoma skin cancer treatment in the US. Dermatol Surg 2001;27:1035-1038.

56. Abbasi NR, Shaw H, Rigel DS, et al. Early diagnosis of cutaneous melanoma. Revisiting the ABCD Criteria. JAMA 2004;292:2771-2776.

57. Acarturk TO, Edington H. Nonmelanoma skin cancer. Clin Plast Surg 2005;32:237-248.

58. Swanson NA, Lee KK, Gorman A, Lee H. Biopsy techniques. Diagnosis of melanoma. Dermatol Clin 2002;20:677-680.

59. Veness MJ. Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma. Aust Radiol 2005;49:365-376.

60. Danson S, Lorigan P. Improving outcomes in advanced malignant melanoma. Drugs 2005;65:733-743.

61. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. The Lancet Oncology 2004;5:497-508.

62. Jorizzo J, Carney P, Ko W, et al. Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: Equivalent efficacy with a lower concentration and more convenient dosing schedule. Cutis 2004;74: 18-23.

63. Morse LG, Kendrick C, Hooper D, et al. Treatment of squamous cell carcinoma with intralesional 5-fluorouracil. Dermatol Surg 2003;29:1150-1153.

64. Burns CA, Brown MD. Imiquimod for the treatment of skin cancer. Dermatol Clin 2005;24:151-164.

65. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005;31:318-323.

66. Patel G, Goodwin R, Chawla BA, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006;54:1025-1032.

67. Tucker S, Polasek JW, Perri AJ, et al. Long-term follow-up of basal cell carcinomas treated with perilesional interferon a 2b as monotherapy. J Am Acad Dermatol 2006;54:1033-1038.

How To Prevent Skin Cancer

How To Prevent Skin Cancer

Complete Guide to Preventing Skin Cancer. We all know enough to fear the name, just as we do the words tumor and malignant. But apart from that, most of us know very little at all about cancer, especially skin cancer in itself. If I were to ask you to tell me about skin cancer right now, what would you say? Apart from the fact that its a cancer on the skin, that is.

Get My Free Ebook


Post a comment